Without a doubt,every day past 50 years old something else seems to hurt.that never hurt before. Bad kind of growing pains. LOL. No but in all seriousness.these individuals in Avxl`s Alz trial were the worst cases,and with that they were old. You never know the endless ailments that the elderly have,besides Alz, so to think that most dropouts were from other reasons related to their health,is the correct conclusion,until told otherwise. What we do know for sure is that the drug is working to stop further deterioration in many,and it`s returning some cognitive functions, so considering that there`s nothing out there currently that`s showing any better results,I`d say we have a better than good chance at approval. What`s this stock price gonna be once Avxl achieves approval for Retts,with the Alz trial running on top? Well while you imagine what the number could be,understand why so many will never sell this stock until this story unfolds,because the stock`s 5 bucks,and can easily become a multi billion dollar market cap company over night. Alz has a yearly cap of 10-30 billion,,so how much of that huge pie will Anavex take when they have the only drug that`s working for it? The sky could truly be the limit,and at 5.34 the risk reward is spectacular. Shorts are toast,,longs are not selling a single share,we`re buying any dips. Sorry shorty.
AI
Market Data 
Markets 
